CAS:1491917-83-9
牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Sacituzumab govitecan (IMMU-132) 是一种抗体-药物偶联物 (ADC),靶向 Trop-2 以递送 SN-38。 Sacituzumab govitecan 具有抗癌活性[1]。
体内:Sacituzumab govitecan (IMMU-132)(17.5 mg/kg;每周两次,持续 4 周)对携带人胃癌异种移植物的小鼠产生显着的抗肿瘤作用[1]。
参考文献:
[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31.
[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.
转载本文请联系原作者获取授权,同时请注明本文来自仇伟伟科学网博客。
链接地址:https://wap.sciencenet.cn/blog-3506747-1427293.html?mobile=1
收藏